Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.34 |
| ▸ | LRP6 | O75581 | 13/20 | 0.81 |
| ▸ | DKK1 | O94907 | 1/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.79 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.34 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.34 |
| ▸ | MAP2 | P11137 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19460949 | 0.87 | LRP6 (0.63) | LRP6DKK1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL20329104 | 0.61 | SLC16A3 (0.40) | LRP6DKK1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL11861328 | 0.61 | SLC16A3 (0.57) | CYP1A2CYP2D6CYP2C19HSD17B10SLC16A3 | |
| SCHEMBL4955063 | 0.60 | CCR4 (0.52) | CYP1A2CYP2C19HIF1AHSD17B10SLC16A3 | |
| SCHEMBL24872303 | 0.60 | KDR (0.48) | CYP2C19HSD17B10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL7675158 | 0.59 | IKBKB (0.49) | HSD17B10SLC16A3MEN1ALDH1A1MAPT | |
| SCHEMBL5342821 | 0.59 | GPR52 (0.47) | CYP1A2CYP2C19HSD17B10MEN1ALDH1A1 | |
| SCHEMBL12316301 | 0.59 | MAOA (0.55) | HIF1AHSD17B10MEN1ALDH1A1MAPT | |
| SCHEMBL7217355 | 0.58 | ALDH1A1 (0.46) | HSD17B10ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL3588485 | 0.58 | ALDH1A1 (0.41) | HSD17B10SLC16A3MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11400027-B2 | Kit and method for detecting porous dental hydroxyapatite | INCISIVE TECHNOLOGIES PTY LTD (AU) | 2022-08-02 | — | — | US | claimed |
| US-20260043720-A1 | STABILIZED TWO-PART HEMATOXYLIN SOLUTION UTILIZING pH ADJUSTMENT | VENTANA MED SYST INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12496344-B2 | Biophotonic materials and uses thereof | FLE INT S R L (IT) | 2025-12-16 | — | — | US | disclosed |
| US-12474240-B2 | Stabilized two-part hematoxylin solution utilizing pH adjustment | VENTANA MEDICAL SYSTEMS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250332393-A1 | DEVICES AND METHODS FOR THE TREATMENT OF BODY SURFACE DISORDERS | VERRICA PHARMACEUTICALS INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250302794-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR THE TREATMENT OF CUTANEOUS DISORDERS | VERRICA PHARMACEUTICALS INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250153421-A1 | GRADIENT PRINTING RESERVOIR AND PRINTING METHOD | AMSILK GMBH (DE) | 2025-05-15 | — | — | US | disclosed |
| US-12290651-B2 | Devices and methods for the treatment of body surface disorders | VERRICA PHARMACEUTICALS INC. (US) | 2025-05-06 | — | — | US | disclosed |
| WO-2025065344-A1 | ANTENNA, USER EQUIPMENT, WINDOW AND VEHICLE | GOERTEK INC. (CN) | 2025-04-03 | — | — | WO | disclosed |
| US-12233042-B2 | Treatment of cutaneous disorders | VERRICA PHARMACEUTICALS INC. (US) | 2025-02-25 | — | — | US | disclosed |
| EP-3622266-B1 | STABILIZED TWO-PART HEMATOXYLIN SOLUTION UTILIZING PH ADJUSTMENT, METHOD FOR STAINING AND KIT | VENTANA MED SYST INC (US) | 2022-08-17 | — | — | EP | disclosed |
| US-11400027-B2 | Kit and method for detecting porous dental hydroxyapatite | INCISIVE TECHNOLOGIES PTY LTD (AU) | 2022-08-02 | — | — | US | disclosed |
| WO-2022155672-A1 | ANTI-MICROBIAL MULTILAYER FABRIC MEDIA AND METHOD FOR MAKING SAME | Shuai Danmeng (US) | 2022-07-21 | — | — | WO | disclosed |
| US-20220219027-A1 | ANTI-MICROBIAL MULTILAYER FABRIC MEDIA AND METHOD FOR MAKING SAME | Shuai Danmeng (US) | 2022-07-14 | — | — | US | disclosed |
| US-11382977-B2 | Biophotonic compositions for treating skin and soft tissue wounds having either or both non-resistant and resistant infections | VETOQUINOL S.A. (FR) | 2022-07-12 | — | — | US | disclosed |
| US-11331257-B2 | Biophotonic compositions and methods for providing biophotonic treatment | KLOX TECHNOLOGIES INC. (CA) | 2022-05-17 | — | — | US | disclosed |
| US-11324823-B2 | Biophotonic materials and uses thereof | KLOX TECHNOLOGIES INC. (CA) | 2022-05-10 | — | — | US | disclosed |
| EP-3151861-B1 | SILICONE-BASED BIOPHOTONIC COMPOSITIONS AND USES THEREOF | KLOX TECH INC (CA) | 2022-04-06 | — | — | EP | disclosed |
| US-20220090993-A1 | STABILIZED TWO-PART HEMATOXYLIN SOLUTION UTILIZING pH ADJUSTMENT | VENTANA MEDICAL SYSTEMS, INC. | 2022-03-24 | — | — | US | disclosed |
| CN-114209688-A | Compositions, methods, and systems for treating skin conditions | 威瑞卡制药公司 | 2022-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12233042-B2 | Treatment of cutaneous disorders | CUTA, CMA1, NISCH | PARP1 4189/4885LRP6 3294/4885DKK1 3500/4885 |
| US-20250332393-A1 | DEVICES AND METHODS FOR THE TREATMENT OF BODY SURFACE DISORDERS | CUTA, TLR5, ATP5PD | PARP1 2777/4885LRP6 3759/4885DKK1 2232/4885 |
| US-20260043720-A1 | STABILIZED TWO-PART HEMATOXYLIN SOLUTION UTILIZING pH ADJUSTMENT | SMCHD1, KIT, CD68 | PARP1 1251/4885LRP6 4416/4885DKK1 4400/4885 |
| US-12290651-B2 | Devices and methods for the treatment of body surface disorders | CUTA, TLR5, TIMM10 | PARP1 2807/4885LRP6 3869/4885DKK1 2198/4885 |
| US-20250302794-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR THE TREATMENT OF CUTANEOUS DISORDERS | CUTA, NISCH, WARS1 | PARP1 4739/4885LRP6 2480/4885DKK1 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.